Michael Kauffman

Michael Kauffman, listed as board member, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Karyopharm Therapeutics Inc., Verastem, Inc. and Adicet Bio, Inc. In total, 160 filings cover trades dated from 19 March 2015 to 21 November 2025.

The open-market side counts 1 purchase for €26k alongside 79 sales for €8.7M. The net balance comes to €8.6M on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 8 share grants and 69 option exercises. 2025 to date brings no purchases and 1 sale.

On 25 November 2025 came the latest disclosure, an open-market sale for €74k in Verastem, Inc. The most recent open-market purchase was published on 2 October 2018, 2,943 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.